- 1 Impact of Synchronized Left Ventricular Pacing in Cardiac Resynchronization Therapy
- 2 Yuichiro Miyazaki <sup>1, 2</sup>, Kohei Ishibashi <sup>\*1</sup>, Nobuhiko Ueda <sup>1</sup>, Satoshi Oka <sup>1, 2</sup>, Akinori
- Wakamiya <sup>1</sup>, Keiko Shimamoto <sup>1</sup>, Kenzaburo Nakajima <sup>1</sup>, Tsukasa Kamakura <sup>1</sup>, Mitsuru Wada <sup>1</sup>,
- 4 <sup>2</sup>, Yuko Inoue <sup>1</sup>, Koji Miyamoto <sup>1</sup>, Satoshi Nagase <sup>1</sup>, Takeshi Aiba <sup>1</sup>, Kengo Kusano <sup>1, 2</sup>
- 6 Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita,
- 7 Japan

- 8 <sup>2</sup> Department of Advanced Cardiovascular Medicine, Graduate School of Medical Sciences,
- 9 Kumamoto University, Kumamoto, Japan
- 10 Short title: Synchronized left ventricular pacing in CRT
- 11 \*Correspondence:
- 12 Kohei Ishibashi, MD, PhD
- 13 Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 6-1
- 14 Kishibe-Shimmachi, Suita, Osaka 564-8565, Japan
- 15 Tel: +81-6-6170-1070
- 16 Fax: +81-6-6170-1348
- 17 E-mail: kohei-ishibashi@ncvc\_go.jp
- 19 **Word count: 3528**

Abstract Background: The adaptive cardiac resynchronization therapy (aCRT) algorithm enables synchronized left ventricular pacing (sLVP) to produce fusion with intrinsic right ventricular activation in normal atrioventricular (AV) conduction. Although sLVP presents benefits over biventricular pacing (BVP), the adequate sLVP rate for better clinical outcomes remains unclear. This study aimed to assess the association between sLVP rates and clinical outcomes. Methods: Among our cohort of 271 consecutive patients who underwent CRT implantation between April 2016 and August 2021, we evaluated 63 patients who underwent CRT without considerably prolonged AV conduction and applied the aCRT algorithm (48 men, mean age: 64 ± 14 years; median follow-up period: 316 days [interquartile range: 212–809 days]). **Results:** At the 6-month follow-up after CRT implantation, the frequency of CRT responders was 71% (n = 45). The sLVP rate was significantly higher in responders than in non-responders  $(75 \pm 30 \text{ vs. } 47 \pm 40 \text{ \%}, p = 0.003)$ . Receiver operating characteristics (ROC) curve analysis revealed that the optimal cut-off value during the sLVP rate was 59.4% for prediction of CRT responders (area under the curve, 0.70; sensitivity, 80%; specificity, 61%; positive predictive value, 84%; and negative predictive value, 55%). Kaplan–Meier analysis demonstrated that the higher sLVP group (sLVP ≥59.4%, n = 43) had better prognosis (cardiac death and heart failure hospitalization) than the lower sLVP group (sLVP <59.4%, n = 20) (log-rank p<0.001), and multivariate Cox hazard analysis revealed that a higher sLVP rate was associated with good prognosis (p<0.001). Conclusion: sLVP was associated with CRT response, and higher sLVP rate (≥59.4%) is important for good prognosis in patients with aCRT.

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

43 **KEYWORDS** 44 Adaptive CRT, cardiac resynchronization therapy, left ventricular pacing, responder 45 **CLINICAL PERSPECTIVE** 46 47 What Is New? 48 • Synchronized left ventricular pacing(sLVP) >59.4% was a significant predictor of cardiac 49 resynchronization therapy(CRT) responders and better clinical outcomes, evidenced by the 50 results of the multivariate analysis. 51 • In this study, which included patients with moderately prolonged PR intervals, high sLVP 52 rates were associated with better clinical outcomes. 53 What Are the Clinical Implications? 54 • sLVP rate was associated with the improvement of cardiac function after CRT implantation. 55 · A higher sLVP rate was associated with a lower risk of cardiac death and heart failure 56 hospitalization. 57 58 LIST OF ABBREVIATIONS 59 aCRT: Adaptive cardiac resynchronization therapy 60 AV: Atrioventricular 61 BVP: Biventricular pacing 62 ECG: Electrocardiogram 63 HF: Heart failure

64

ICM: Ischaemic cardiomyopathy

- 65 LBBB: Left bundle branch block
- 66 LVEF: Left ventricular ejection fraction
- 67 LVESV: Left ventricular end-systolic volume
- 68 NYHA: New York Heart Association
- 69 ROC: Receiver operating characteristics
- 70 SPECT: Single-photon emission computed tomography
- 71 sLVP: Synchronized left ventricular pacing
- 72 VV: Interventricular

#### 1 INTRODUCTION

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

Cardiac resynchronization therapy (CRT) improves cardiac function and clinical outcomes in patients with symptomatic heart failure accompanied by decreased left ventricular ejection fraction (LVEF), QRS prolongation, and left bundle branch block (LBBB) (1). However, up to 30% of patients do not see improvements in cardiac function and/or clinical prognosis after CRT implantation (2). The Adaptive CRT algorithm (aCRT) is a novel pacing algorithm for CRT that continuously optimises the atrioventricular (AV) and the interventricular (VV) delays based on heart rate and intrinsic AV conduction (3). In cases whereby the AV interval is shorter than 220 ms (during atrial sensing) or 270 ms (during atrial pacing), the aCRT algorithm uses the RV intrinsic conduction, which can provide synchronized left ventricular pacing (sLVP) to create fusion beat with the intrinsic conduction. In cases where the AV interval is extremely prolonged, the aCRT pacing provides biventricular pacing (BVP) without fusion with the intrinsic conduction. The sLVP was reported to have benefits over BVP regarding the risk of heart failure (HF), hospitalization, cardiac death, or atrial fibrillation (4,5). However, the adequate sLVP rate for better clinical outcomes remains unclear. This novel study aimed to assess the appropriate sLVP rate for recovering cardiac function in the mid-term, and to improve clinical outcomes in the long-term.

#### 2 METHODS

## 2.1 Study population

This retrospective single-centre study included all consecutive patients who underwent CRT device implantation featuring the Adaptive CRT algorithm (Medtronic Inc., Minneapolis, MN, USA) (aCRT) between April 1, 2016, and August 31, 2021. The aCRT pacing mode was adapted just after the implantation. Patients who applied the pacing algorithm without adopting sLVP mode were excluded from this analysis. In addition, patients with persistent atrial

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

fibrillation, AV block, and extremely prolonged PR also were excluded from this analysis, due to difficulty in using sLVP. This study was conducted in accordance with the principles outlined in the Declaration of Helsinki and approved by the ethics committee of our institution (M26-150-10). This is a retrospective study to analyze the anonymous data generated after patients have agreed to treatment; we applied the opt-out method to obtain informed consent. 2.2 Study protocol The patients enrolled in this study were classified into two groups (CRT responder or non-responder) depending on the response to CRT pacing 6 months after CRT implantation. Next, we determined the required sLVP rate to become a CRT responder using a receiver operating characteristic (ROC) curve analysis. Thereafter, we compared the association between the sLVP rate and clinical prognosis. 2.3 Cardiac examinations and definition of responses before and after CRT implantation Cardiac systolic function was assessed using both echocardiography and single-photon emission computed tomography (SPECT) before and 6 months after CRT device implantation. Electrocardiogram (ECG)-gated myocardial perfusion SPECT imaging with technetium-99m (99mTc) sestamibi was performed to measure cardiac systolic function and dimensions. All echocardiographic data were measured during three consecutive cardiac cycles. The left ventricular end-systolic volume (LVESV) and LVEF were measured using Simpson's biplane method. CRT responders were described as patients with an improved LVEF >10% and/or reduced

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

LVESV > 15% 6 months after CRT device implantation compared with baseline. Cardiac death and/or hospitalization for HF were evaluated as clinical outcomes. Cardiac death was defined as HF death, left ventricular assist device implantation, or death from ventricular arrhythmia. HF hospitalization was defined as a sudden or gradual onset of symptoms of New York Heart Association (NYHA) functional class III or IV HF, requiring unplanned hospitalization. 2.4 Statistical analyses Data were analyzed using JMP software (version 11.2.01, SAS Institute, Cary, NC, USA). Continuous variables are presented as mean  $\pm$  standard deviation and were compared using Student's t-test. Categorical variables were compared using Fisher's exact test. The cumulative incidence and event-free curves were based on Kaplan-Meier analyses, stratified by study group, and contrasted using the log-rank test. Hazard ratios and odds ratios are reported with their 95% confidence intervals. To identify independent predictors of clinical response, univariable analyses were first performed, and predictors with a significance level <5%, age, and sex were included in the multivariable models. Multivariable analyses were performed using a Cox regression model. P-values of <0.05 were considered reflective of statistically significant differences. 3 RESULTS 3.1 **Patient characteristics** Among our cohort of 271 consecutive patients who underwent CRT implantation between April 2016 and August 2021, we evaluated 63 patients who underwent CRT without considerably prolonged AV conduction on whom we applied the aCRT algorithm (48 men, mean age:  $64 \pm 14$  years) (Figure 1). The baseline characteristics of the patients are shown in

Table 1. The number of patients with ischaemic cardiomyopathy (ICM) was 17 (27%), and

148 mean LVEF was 23  $\pm$  7%. Mean PR and QRS time were 192  $\pm$  32 ms and 155  $\pm$  25 ms, 149 respectively, and the number of patients with LBBB was 31 (49%). 150 151 3.2 CRT responder and synchronized left ventricular pacing rate 152 At the 6-month follow-up after CRT implantation, the frequency of CRT responders was 71% 153 (n = 45) (Table 1). Patients with LBBB were significantly more frequent than those without. 154 There was no significant difference in the QRS width and rate of ICM. The sLVP rate was 155 significantly higher in responders than in non-responders (75  $\pm$  30 vs. 47  $\pm$  40%, p = 0.003). 156 ROC curve analysis revealed that the optimal cut-off value during sLVP rate was 59.4% for the 157 prediction of CRT responders (area under the curve, 0.71; sensitivity, 80%; specificity, 61%; 158 positive predictive value, 84%; and negative predictive value, 55%) (Figure 2). Multivariate 159 analysis showed that sLVP >59.4% was an independent responder for CRT responder (odds 160 ratio: 4.52, 95% CI: 1.18–18.90, p = 0.027) (Table 2). 161 162 3.3 Clinical outcome of high sLVP rate 163 During a median follow-up of 346 days (IQR, 223-760 days), one patient had cardiac death 164 and 13 patients had HF hospitalizations. Five patients died during hospitalization because of 165 HF. Kaplan–Meier analysis demonstrated that the high sLVP group (sLVP  $\geq$ 59.4%, n = 43) had 166 a better prognosis (cardiac death and HF hospitalization) than the low sLVP group (sLVP 167 <59.4%, n = 20) (log-rank p<0.001) (Figure 3), and multivariate Cox hazard analysis revealed 168 that higher sLVP rate was associated with good prognosis (hazard ratio: 0.10, 95% CI: 0.01– 169 0.40, p = 0.027, p < 0.001) (Table 3).

170

### 4 DISCUSSION

## **Main findings**

- 174 The main findings of this study are as follows: (1) CRT responders had higher sLVP rates than
- 175 CRT non-responders, (2) sLVP >59.4% was an excellent predictor of CRT response, and (3)
- 176 sLVP >59.4% led to fewer cardiac deaths and hospitalizations due to HF.

## The mechanism of fusion beat of pacing and intrinsic conduction

Recent CRT devices have the function to automatically adjust the fusion beat of self AV conduction and pacing. This regulatory function seems to lead to further narrowing of the QRS width after the CRT implantation (6). Previous studies have reported that the narrowing of QRS width after the CRT implantation can improve echocardiographic outcomes and long-term mortality (7,8). In addition to the function of adjusting the fusion beat, other studies have reported that sLVP could shorten QRS width compared with BVP (9,10). The sLPV may contribute to improved responder rate and better clinical outcomes by achieving QRS narrowing by creating the fusion beat with the intrinsic waveform and pacing.

## The adequate frequency of synchronized left ventricular pacing

Adaptive CRT has an automatic adjustment algorithm for AV and interventricular delays based on frequent AV conduction evaluations. Furthermore, sLVP is often used for normal AV conduction (9). A previous study showed that sLVP provided better clinical outcomes than conventional BVP (4); however, the frequency of sLVP that leads to a better prognosis is not well known. Previous studies have defined the cut-off rate of sLVP to be 80% to predict clinical and echocardiographic parameters (9). Another study reported that an sLVP rate >50% was associated with better clinical outcomes compared with that of <50% (4). However, these rates are not statistically determined values. In this study, sLVP >59.4% was a significant predictor

of CRT responders and better clinical outcomes, evidenced by the results of the multivariate analysis. Using this criterion, we may be able to predict clinical responses, such as cardiac death and HF hospitalization.

### The association between synchronized left ventricular pacing and PR interval

A previous study reported that LVP improved LV dp/dt max in patients with a PR interval <200 ms (11). Other studies have also reported the effect of sLVP in patients with a normal PR interval (9,10); however, the significance of sLVP in patients with prolonged PR intervals is unknown. In this study, which included patients with moderately prolonged PR intervals, high sLVP rates were associated with better clinical outcomes. However, the patients with sLVP <59.4% had longer PR intervals than the patients with sLVP >59.4%. The sLVP rate appeared significantly affected by PR interval, especially in patients with prolonged PR intervals. Prolonged PR intervals are considered a significant factor in preventing a high sLVP rate. A previous report showed that RA septal pacing was associated with a shorter AV interval than right appendage pacing (12). The case report demonstrated that the sLVP rate was increased by RA septal pacing in patients with extremely prolonged PR intervals (424 ms). In this study, most patients experienced right appendage pacing. We should consider that the RA pacing lead is positioned at the RA septum in patients with a prolonged PR interval to increase the LPV rate.

## 5 STUDY LIMITATIONS

This study had some limitations. First, this was a retrospective single-centre study. The results of this study should be further confirmed by prospective and multi-centre studies in the future. Second, the sample size was small, which reduces the statistical strength of our findings. In order to resolve this point, it is necessary to collect cases in a multi-center study. Third, the

current study compared the mixture of sLVP and BVP. To clarify the effect of the sLVP, we have to compare the pure sLVP and the pure BVP.

6 CONCLUSIONS

Our study shows that the sLVP rate is associated with the CRT responder rate. A higher sLVP rate (>59.4%) is associated with a lower risk of cardiac death and HF hospitalization.

Data Availability: The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Sources of Funding: This research did not receive any specific grants from funding agencies in the public, commercial or not-for-profit sectors.

Disclosures: None.

237 REFERENCES 238 1. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, 239 Packer M, Clavell AL, Hayes DL, et al. Cardiac Resynchronization in Chronic 240 Heart Failure. New England Journal of Medicine. 2002;346:1845–1853. 241 2. Pitzalis MV, Iacoviello M, Romito R, Massari F, Rizzon B, Luzzi G, Guida P, 242 Andriani A, Mastropasqua F, Rizzon P. Cardiac Resynchronization Therapy 243 Tailored by Echocardiographic Evaluation of Ventricular Asynchrony. Journal of 244 the American College of Cardiology. 2002;40:1615–1622. 245 3. Martin DO, Lemke B, Birnie D, Krum H, Lee KL, Aonuma K, Gasparini M, 246 Starling RC, Milasinovic G, Rogers T, et al. Investigation of a Novel Algorithm 247 for Synchronized Left-Ventricular Pacing and Ambulatory Optimization of 248 Cardiac Resynchronization Therapy: Results of the Adaptive CRT Trial. Heart 249 Rhythm. 2012;9:1807–1814. 250 4. Birnie D, Lemke B, Aonuma K, Krum H, Lee KL, Gasparini M, Starling RC, 251 Milasinovic G, Gorcsan J, Houmsse M et al. Clinical Outcomes with 252 Synchronized Left Ventricular Pacing: Analysis of the Adaptive CRT Trial. Heart 253 Rhythm. 2013;10:1368–1374. 254 5. Hsu JC, Birnie D, Stadler RW, Cerkvenik J, Feld GK, Birgersdotter-Green U. 255 Adaptive Cardiac Resynchronization Therapy Is Associated with Decreased Risk 256 of Incident Atrial Fibrillation Compared to Standard Biventricular Pacing: A 257 Real-World Analysis of 37,450 Patients Followed by Remote Monitoring. Heart 258 Rhythm. 2019;16:983–989. 259 6. Thibault B, Ritter P, Bode K, Calò L, Mondésert B, Mangual JO, Badie N, 260 McSpadden LC, Pappone C, Varma N. Dynamic Programming of Atrioventricular

Delay Improves Electrical Synchrony in a Multicenter Cardiac Resynchronization

- 262 Therapy Study. *Heart Rhythm*. 2019;16:1047–1056. 7. 263 Jastrzebski M, Baranchuk A, Fijorek K, Kisiel R, Kukla P, Sondej T, Czarnecka D. 264 Cardiac Resynchronization Therapy-Induced Acute Shortening of QRS Duration 265 Predicts Long-Term Mortality Only in Patients with Left Bundle Branch Block. 266 Europace. 2019;21:281-289. Hsing JM, Selzman KA, Leclercq C, Pires LA, Mclaughlin MG, Mcrae SE, 267 8. 268 Peterson BJ, Zimetbaum PJ. Paced Left Ventricular QRS Width and ECG 269 Parameters Predict Outcomes after Cardiac Resynchronization Therapy: 270 PROSPECT-ECG Substudy. Circulation. Arrhythmia and Electrophysiology. 271 2011;4:851–857. 272 9. Burns KV, Gage RM, Curtin AE, Gorcsan III J, Bank AJ. Left Ventricular-Only 273 Pacing in Heart Failure Patients with Normal Atrioventricular Conduction 274 Improves Global Function and Left Ventricular Reginal Mechanics Compared 275 with Biventricular Pacing: an Adaptive Cardiac Resynchronisation Therapy 276 Sub-study. European Journal of Heart Failure. 2017;29:1335–1343. 277 10. Su Y, Hua W, Shen F, Zou J, Tang B, Chen K, Liang Y, He L, Zhou X, Zhang X, et 278 al. Left Ventricular-Only Fusion Pacing versus Cardiac Resynchronization 279 Therapy in Heart Failure Patients: A Randomized Controlled Trial. Clinical 280 Cardiology. 2021;44:1225–1232. 281 11. Van Gelder BM, Bracke FA, Meijer A, Pijls NH. The Hemodynamic Effect of 282 Intrinsic Conduction during Left Ventricular Pacing as Compared to Biventricular 283 Pacing. Journal of the American College of Cardiology. 2005;46:2305–2310.
- 284 12. Murata Y, Ishibashi K, Yamagata K, Izumi C, Noguchi T, Kusano K. Impact of 285 Atrial Septal Pacing in Left Ventricular-Only Pacing in Patients with a 286 First-Degree Atrioventricular Block: A Case Series. *HeartRhythm Case Reports*.

2022;8:187–190.

# **TABLES**

288

289

Table 1. Baseline characteristics between responders and non-responders

	All patients $(n = 63)$	Responder $(n = 45)$	Non-responder $(n =$	P-Val	
			18)	ue	
Age, years	64 ± 14	65 ± 13	63 ± 15	P	=
				0.58	36
Men	48 (76%)	34 (76%)	14 (78%)	P	>
				0.99	99
Height, cm	$166 \pm 9$	$166 \pm 9$	$166 \pm 9$	P	=
				0.98	34
Body	61 ± 13	63 ± 12	57 ± 14	P	=
weight, kg				0.09	93
CRT-D/CRT	56/7	38/7	18/0	P	=
-P				0.17	77
Secondary	10 (16%)	5 (11%)	5 (28%)	P	=
prevention				0.13	32
NYHA,	44(70%)/15(24%)/4(	32(71%)/11(24%)/2(	12(67%)/4(22%)/2(1	P	=
II/III/IV	6%)	4%)	1%)	0.61	17
ICM	17 (27%)	9 (20%)	8 (44%)	P	=
				0.06	63
HT	23 (37%)	19 (42%)	4 (22%)	P	=
				0.15	59
DM	18 (29%)	15 (33%)	3 (17%)	P	=

				0.230
CKD	31 (49%)	21 (47%)	10 (56%)	P =
				0.585
LVEF, %	$23 \pm 7$	$22 \pm 7$	$24 \pm 8$	P =
				0.386
LVESV, mL	$181 \pm 80$	$178 \pm 84$	$190\pm70$	P =
				0.630
PR time, ms	$192 \pm 32$	$188 \pm 31$	$204 \pm 34$	P =
				0.084
QRS time,	$155 \pm 25$	$159 \pm 27$	$146\pm18$	P =
ms				0.057
LBBB	31 (49%)	27 (60%)	4 (22%)	P =
				0.011
LV only	$67 \pm 35$	$75 \pm 30$	$47 \pm 40$	P =
pacing, %				0.003
Cre, mg/dL	$1.2\pm0.6$	$1.2\pm0.7$	$1.2\pm0.4$	P =
				0.817
BNP, pg/mL	$401 \pm 473$	$352 \pm 474$	$525 \pm 459$	P =
				0.1913

Data are presented as the mean  $\pm$  standard deviation or number (percentage).

Abbreviations: BNP, brain natriuretic peptide; CKD, chronic kidney disease; Cre, creatinine; CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization therapy pacemaker; DM, diabetes mellitus; HT, hypertension; ICM, ischaemic cardiomyopathy; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; NICM, non-ischaemic cardiomyopathy; NYHA,

New York Heart Association.

297

Table 2. Univariate and multivariate analyses for responder

	Univariate analysis		Multivariate analysis			
	OR	95% CI	<i>P</i> -value	OR	95% CI	<i>P</i> -value
Age, 1 year	0.98	0.94–1.02	0.580	0.98	0.93-1.03	0.647
increase						
Men	0.88	0.21-3.09	0.850	0.65	0.12-2.92	0.589
ICM	0.31	0.09-1.02	0.054			
HT	2.55	0.77-10.13	0.126			
DM	2.50	0.68-11.99	0.170			
CKD	0.70	0.22-2.09	0.523			
LVEF, 1%	1.03	0.95-1.11	0.383			
increase						
LVESV, 1 mL	1.00	0.99-1.00	0.631			
increase						
PR, 1 ms	1.01	0.99-1.03	0.081			
increase						
QRS, 1 ms	0.97	0.95-1.00	0.051			
increase						
LBBB	5.25	1.59–20.91	0.005	2.81	0.68-12.76	0.149
sLVP>59.4%	6.28	1.95–21.91	0.001	4.52	1.18-18.90	0.027

Abbreviations: BNP, brain natriuretic peptide; CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; HT, hypertension; ICM, ischaemic cardiomyopathy; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; OR, odds ratio; sLVP, synchronized left ventricular pacing.

Table 3. Univariate and multivariate analyses for cardiac death and heart failure hospitalization

	Univariate analysis		Multivariate analysis			
	HR	95% CI	<i>P</i> -value	HR	95% CI	<i>P</i> -value
Age, 1 year	0.99	0.96–1.04	0.972	0.95	0.90-1.00	0.061
increase						
Men	0.68	0.22-2.53	0.541	0.63	0.15–2.88	0.541
ICM	2.51	0.82-7.32	0.102			
HT	0.28	0.04-1.03	0.055			
DM	1.00	0.27-3.04	0.999			
CKD	3.72	1.23-13.72	0.019	14.51	2.79–108.45	< 0.001
LVEF, 1%	0.97	0.89-1.04	0.521			
increase						
LVESV, 1 mL	1.00	0.99-1.00	0.994			
increase						
PR, 1 ms	1.01	0.99-1.03	0.060			
increase						
QRS, 1 ms	0.98	0.96-1.00	0.149			
increase						
LBBB	0.26	0.05-0.84	0.023	0.41	0.08-1.55	0.198
sLVP>59.4%	0.12	0.02-0.40	< 0.001	0.10	0.01-0.40	< 0.001

Abbreviations: CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; HR, hazard ratio; HT, hypertension; ICM, ischaemic cardiomyopathy; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; sLVP, synchronized left ventricular pacing.

### **FIGURES**

310




Figure 1. Overview of the study population

- 313 Among our cohort of 271 consecutive patients who underwent CRT implantation between
- 314 April 2016 and August 2021, we evaluated 63 sLPV enabled CRT patients and applied the
- 315 aCRT algorithm.
- 316 Abbreviations: AF, atrial fibrillation; AV, atrioventricular; CRT, cardiac resynchronization
- 317 therapy; sLVP, synchronized left ventricular pacing.





Figure 2. The association between CRT responder and synchronized left ventricular pacing rate

Receiver operating characteristic curve analysis revealed that the optimal cut-off value during

pacing

sLVP rate was 59.4% for the prediction of CRT responders.

Abbreviations: CRT, cardiac resynchronization therapy; sLVP, synchronized left ventricular



**Figure 3** Kaplan–Meier analysis. The analysis demonstrates that the higher sLVP group (sLVP>59.4%, n = 43) had better prognosis (with regard to cardiac death and heart failure hospitalization) than the lower sLVP group (sLVP<59.4%, n = 20) (log-rank p<0.001). Abbreviations: sLVP, synchronized left ventricular pacing.